These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 21928610)

  • 1. Patient outcomes, economic benefits associated with a heparin change in hemodialysis, and nurses' satisfaction.
    Chevalier BA; Hudson S; Thompson K; Constantine C
    Nephrol Nurs J; 2011; 38(4):339-48. PubMed ID: 21928610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tinzaparin reduces health care resource use for anticoagulation in hemodialysis.
    Pettigrew M; Soltys GI; Bell RZ; Daniel N; Davis JR; Senecal L; Leblanc M
    Hemodial Int; 2011 Apr; 15(2):273-9. PubMed ID: 21338468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the two-year outcomes and costs of prophylaxis in medical patients at risk of venous thromboembolism.
    Deitelzweig SB; Becker R; Lin J; Benner J
    Thromb Haemost; 2008 Nov; 100(5):810-20. PubMed ID: 18989525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticoagulation therapy during haemodialysis: a comparative study between two heparin regimens.
    Sabry A; Taha M; Nada M; Al Fawzan F; Alsaran K
    Blood Coagul Fibrinolysis; 2009 Jan; 20(1):57-62. PubMed ID: 20523166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trisodium citrate: an alternative to unfractionated heparin for hemodialysis catheter dwells.
    Pierce DA; Rocco MV
    Pharmacotherapy; 2010 Nov; 30(11):1150-8. PubMed ID: 20973688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost comparison of at-home treatment of deep venous thrombosis with low molecular weight heparin to inpatient treatment with unfractionated heparin.
    Smith BJ; Weekley JS; Pilotto L; Howe T; Beven R
    Intern Med J; 2002; 32(1-2):29-34. PubMed ID: 11783670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should hemodialysis patients with atrial fibrillation undergo systemic anticoagulation? A cost-utility analysis.
    Quinn RR; Naimark DM; Oliver MJ; Bayoumi AM
    Am J Kidney Dis; 2007 Sep; 50(3):421-32. PubMed ID: 17720521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of dalteparin versus unfractionated heparin as venous thromboembolism prophylaxis in malignant gynecologic surgery.
    Wade WE; Spruill WJ
    Am J Ther; 2008; 15(6):512-5. PubMed ID: 19127133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective.
    Hull RD; Raskob GE; Pineo GF; Feldstein W; Rosenbloom D; Gafni A; Green D; Feinglass J; Trowbridge AA; Elliott CG
    Arch Intern Med; 1997 Feb; 157(3):298-303. PubMed ID: 9040296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Management of heparin-induced thrombocytopenia in a patient on hemodialysis complicated with thrombosis in the extracorporeal circuit].
    César JM; Candela A; Tenorio MT; Chinea A; Sáiz R; Liaño F
    Nefrologia; 2008; 28(4):462-3. PubMed ID: 18662159
    [No Abstract]   [Full Text] [Related]  

  • 11. The relationships between nurses' perceptions of the hemodialysis unit work environment and nurse turnover, patient satisfaction, and hospitalizations.
    Gardner JK; Thomas-Hawkins C; Fogg L; Latham CE
    Nephrol Nurs J; 2007; 34(3):271-81; quiz 282. PubMed ID: 17644871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low molecular weight heparin versus unfractionated heparin in the colonoscopy peri-procedure period: a cost modeling study.
    Goldstein JL; Larson LR; Yamashita BD; Fain JM; Schumock GT
    Am J Gastroenterol; 2001 Aug; 96(8):2360-6. PubMed ID: 11513175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronically anticoagulated patients who need surgery: can low-molecular-weight heparins really be used to "bridge" patients instead of intravenous unfractionated heparin?
    Jaff MR
    Catheter Cardiovasc Interv; 2009 Jul; 74 Suppl 1():S17-21. PubMed ID: 19213061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of heparin and dalteparin on oxidative stress during hemodialysis in patients with end-stage renal disease.
    Nassiri AA; Hakemi MS; Soulati M; Marashian M; Rahbar K; Azizi F
    Iran J Kidney Dis; 2009 Jul; 3(3):162-7. PubMed ID: 19617666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outpatient treatment of venous thromboembolism with low-molecular-weight heparin: an economic evaluation.
    Huse DM; Cummins G; Taylor DC; Russell MW
    Am J Manag Care; 2002 Jan; 8(1 Suppl):S10-6. PubMed ID: 11822346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enoxaparin versus unfractioned heparin as anticoagulant for continuous venovenous hemodialysis: a randomized open-label trial.
    Garcés EO; Victorino JA; Thomé FS; Röhsig LM; Dornelles E; Louzada M; Stifft J; de Holanda F; Veronese FV
    Ren Fail; 2010 Jan; 32(3):320-7. PubMed ID: 20370447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost-effectiveness of diagnostic strategies in patients with suspected pulmonary embolism.
    Michel BC; Seerden RJ; Rutten FF; Van Beek EJ; Büller HR
    Health Econ; 1996; 5(4):307-18. PubMed ID: 8880167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and economic implications of heparin-induced thrombocytopenia in medical patients receiving prophylaxis for venous thromboembolism.
    Creekmore FM; Oderda GM; Pendleton RC; Brixner DI
    Pharmacotherapy; 2006 Oct; 26(10):1438-45. PubMed ID: 16999654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and economic outcomes in patients at risk of venous thromboembolism receiving appropriate enoxaparin or unfractionated heparin prophylaxis.
    Amin AN; Lin J; Lenhart G; Schulman KL
    Thromb Haemost; 2009 Aug; 102(2):321-6. PubMed ID: 19652883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic evaluation of the use of enoxaparin in non-ST-elevation acute coronary syndrome.
    Nutescu EA; Steinmetz Pater K
    Expert Opin Pharmacother; 2008 Jan; 9(1):95-105. PubMed ID: 18076341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.